Continuous Glucose Monitoring Systems (CGM)

Eversense^® 365^*1&2 is the industry’s first and only fully implantable one-year continuous glucose monitoring (CGM) system. It allows people with diabetes to automatically track glucose values with an inserted sensor placed under the skin. Worn over the implantable sensor, the smart transmitter wirelessly sends data to the user’s mobile device, with the ability to easily remove and reapply the transmitter as it fits their lifestyle^*3. With exceptional and consistent accuracy throughout the lifetime of the sensor, including during hypoglycemia, people with diabetes can count on their readings.

1 Ascensia is the exclusive global distribution partner for the Eversense^® continuous glucose monitoring systems from Senseonics.
2 The Eversense^® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense^® 365 and up to 180 days for Eversense^® E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 13 for Eversense^® 365 and one time per day after day 21 for Eversense^® E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense^® CGM Systems are prescription devices; patients should talk to their health care provider to learn more.
3 There is no glucose data generated when the transmitter is removed.

Learn more about Eversense